US5466806A
(en)
*
|
1989-02-08 |
1995-11-14 |
Biochem Pharma Inc. |
Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
|
US6903224B2
(en)
*
|
1988-04-11 |
2005-06-07 |
Biochem Pharma Inc. |
Substituted 1,3-oxathiolanes
|
US5047407A
(en)
|
1989-02-08 |
1991-09-10 |
Iaf Biochem International, Inc. |
2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
|
US5684164A
(en)
|
1988-04-11 |
1997-11-04 |
Biochem Pharma Inc. |
Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
|
US5270315A
(en)
*
|
1988-04-11 |
1993-12-14 |
Biochem Pharma Inc. |
4-(purinyl bases)-substituted-1,3-dioxlanes
|
US7119202B1
(en)
|
1989-02-08 |
2006-10-10 |
Glaxo Wellcome Inc. |
Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
|
US6350753B1
(en)
|
1988-04-11 |
2002-02-26 |
Biochem Pharma Inc. |
2-Substituted-4-substituted-1,3-dioxolanes and use thereof
|
AU3154993A
(en)
*
|
1989-02-08 |
1994-07-19 |
Biochem Pharma Inc. |
Process for preparing substituted 1,3-oxathiolanes with antiviral properties
|
UA45942A
(uk)
*
|
1989-02-08 |
2002-05-15 |
Біокем Фарма, Інк. |
1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
|
US6069252A
(en)
*
|
1990-02-01 |
2000-05-30 |
Emory University |
Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
|
US6642245B1
(en)
|
1990-02-01 |
2003-11-04 |
Emory University |
Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
|
US5276151A
(en)
*
|
1990-02-01 |
1994-01-04 |
Emory University |
Method of synthesis of 1,3-dioxolane nucleosides
|
US6703396B1
(en)
|
1990-02-01 |
2004-03-09 |
Emory University |
Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
|
US5204466A
(en)
*
|
1990-02-01 |
1993-04-20 |
Emory University |
Method and compositions for the synthesis of bch-189 and related compounds
|
US5700937A
(en)
*
|
1990-02-01 |
1997-12-23 |
Emory University |
Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
|
GB9009861D0
(en)
|
1990-05-02 |
1990-06-27 |
Glaxo Group Ltd |
Chemical compounds
|
US6369066B1
(en)
|
1990-11-13 |
2002-04-09 |
Biochem Pharma, Inc. |
Substituted 1,3-oxathiolanes with antiviral properties
|
WO1992008717A1
(fr)
*
|
1990-11-13 |
1992-05-29 |
Biochem Pharma Inc. |
1,3-oxathiolanes substitues et 1,3-dithiolanes substitutes presentant des caracteristiques antivirales
|
US6228860B1
(en)
|
1990-11-13 |
2001-05-08 |
Biochem Pharma Inc. |
Substituted 1,3-oxathiolanes with antiviral properties
|
US5587480A
(en)
*
|
1990-11-13 |
1996-12-24 |
Biochem Pharma, Inc. |
Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
|
US5444063A
(en)
*
|
1990-12-05 |
1995-08-22 |
Emory University |
Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
|
WO1992010496A1
(fr)
*
|
1990-12-05 |
1992-06-25 |
University Of Georgia Research Foundation, Inc. |
NUCLEOSIDES DE β-L-(-)-1,3-OXATHIOLANE ENANTIOMERIQUEMENT PURS
|
US5179104A
(en)
*
|
1990-12-05 |
1993-01-12 |
University Of Georgia Research Foundation, Inc. |
Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
|
US5248776A
(en)
*
|
1990-12-05 |
1993-09-28 |
University Of Georgia Research Foundation, Inc. |
Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
|
US5925643A
(en)
*
|
1990-12-05 |
1999-07-20 |
Emory University |
Enantiomerically pure β-D-dioxolane-nucleosides
|
IL100502A
(en)
*
|
1991-01-03 |
1995-12-08 |
Iaf Biochem Int |
PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
|
IL100965A
(en)
*
|
1991-02-22 |
1999-12-31 |
Univ Emory |
2 - Hydroxymethyl - 5 -) 5 - Fluorocytocin - 1 - Eyal (- 1, 3 - Oxathiolane, its resolution and pharmaceuticals containing it
|
KR100270806B1
(ko)
*
|
1991-03-06 |
2000-11-01 |
템블 존 엘 |
5-플루오로-2`-데옥시-3`-티아시티딘을 함유하는 b형 간염 치료를 위한 약제
|
GB9104740D0
(en)
*
|
1991-03-06 |
1991-04-17 |
Wellcome Found |
Antiviral nucleoside combination
|
US6812233B1
(en)
*
|
1991-03-06 |
2004-11-02 |
Emory University |
Therapeutic nucleosides
|
WO1992018517A1
(fr)
*
|
1991-04-17 |
1992-10-29 |
Yale University |
Procede de traitement ou de prevention du virus de l'hepatite b
|
US5817667A
(en)
*
|
1991-04-17 |
1998-10-06 |
University Of Georgia Research Foudation |
Compounds and methods for the treatment of cancer
|
GB9109506D0
(en)
*
|
1991-05-02 |
1991-06-26 |
Wellcome Found |
Therapeutic nucleosides
|
DK0513917T4
(da)
*
|
1991-05-16 |
2001-06-25 |
Glaxo Group Ltd |
Antivirale kombinationer indeholdende nukleosidanaloger
|
GB9110874D0
(en)
*
|
1991-05-20 |
1991-07-10 |
Iaf Biochem Int |
Medicaments
|
ZA923640B
(en)
*
|
1991-05-21 |
1993-02-24 |
Iaf Biochem Int |
Processes for the diastereoselective synthesis of nucleosides
|
GB9111902D0
(en)
*
|
1991-06-03 |
1991-07-24 |
Glaxo Group Ltd |
Chemical compounds
|
GB9116601D0
(en)
*
|
1991-08-01 |
1991-09-18 |
Iaf Biochem Int |
1,3-oxathiolane nucleoside analogues
|
DE69120069T2
(de)
*
|
1991-09-04 |
1996-10-02 |
Stichting Rega V Z W |
Substituierte Nukleosidderivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
|
US20050192299A1
(en)
*
|
1992-04-16 |
2005-09-01 |
Yung-Chi Cheng |
Method of treating or preventing hepatitis B virus
|
US6177435B1
(en)
|
1992-05-13 |
2001-01-23 |
Glaxo Wellcome Inc. |
Therapeutic combinations
|
ATE184787T1
(de)
*
|
1992-05-13 |
1999-10-15 |
Wellcome Found |
Therapeutische kombinationen
|
US6005107A
(en)
*
|
1992-12-23 |
1999-12-21 |
Biochem Pharma, Inc. |
Antiviral compounds
|
US6444656B1
(en)
|
1992-12-23 |
2002-09-03 |
Biochem Pharma, Inc. |
Antiviral phosphonate nucleotides
|
GB9226879D0
(en)
*
|
1992-12-23 |
1993-02-17 |
Iaf Biochem Int |
Anti-viral compounds
|
GB9311709D0
(en)
*
|
1993-06-07 |
1993-07-21 |
Iaf Biochem Int |
Stereoselective synthesis of nucleoside analogues using bicycle intermediate
|
US20020120130A1
(en)
*
|
1993-09-10 |
2002-08-29 |
Gilles Gosselin |
2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
|
CA2171550C
(fr)
*
|
1993-09-10 |
2008-08-26 |
Raymond F. Schinazi |
Nucleosides avec activite virale anti-hepatite b
|
US5587362A
(en)
*
|
1994-01-28 |
1996-12-24 |
Univ. Of Ga Research Foundation |
L-nucleosides
|
IL113432A
(en)
*
|
1994-04-23 |
2000-11-21 |
Glaxo Group Ltd |
Process for the diastereoselective synthesis of nucleoside analogues
|
FR2720397B1
(fr)
*
|
1994-05-24 |
1996-08-23 |
Laphal Laboratoires Sa |
Nouveaux oxathiolanes, leur procédé de préparation et les compositions pharmaceutiques qui en renferment.
|
IL115156A
(en)
*
|
1994-09-06 |
2000-07-16 |
Univ Georgia |
Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
|
US6391859B1
(en)
|
1995-01-27 |
2002-05-21 |
Emory University |
[5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
|
US5703058A
(en)
*
|
1995-01-27 |
1997-12-30 |
Emory University |
Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
|
US5808040A
(en)
*
|
1995-01-30 |
1998-09-15 |
Yale University |
L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
|
MY115461A
(en)
|
1995-03-30 |
2003-06-30 |
Wellcome Found |
Synergistic combinations of zidovudine, 1592u89 and 3tc
|
AU5527196A
(en)
*
|
1995-04-04 |
1996-10-23 |
Brigham And Women's Hospital |
Inhibiting retroviral replication
|
ES2276404T3
(es)
*
|
1995-06-07 |
2007-06-16 |
Emory University |
Nucleosidos con actividad antivirus de la hepatitis-b.
|
GB9605293D0
(en)
*
|
1996-03-13 |
1996-05-15 |
Glaxo Group Ltd |
Medicaments
|
FR2746396B1
(fr)
*
|
1996-03-20 |
1998-06-05 |
Inst Nat Sante Rech Med |
1,3-thiazolidin-4-ones et 1,3-thiazolidines substituees, procede d'obtention de ces composes et leurs utilisations comme medicaments
|
EP0938321B1
(fr)
|
1996-06-25 |
2004-01-14 |
Glaxo Group Limited |
Combinaisons comprenant du vx478, de la zidovudine et du 3tc pouvant etre utilisees dans le traitement du vih
|
US5753789A
(en)
*
|
1996-07-26 |
1998-05-19 |
Yale University |
Oligonucleotides containing L-nucleosides
|
US6113920A
(en)
*
|
1996-10-31 |
2000-09-05 |
Glaxo Wellcome Inc. |
Pharmaceutical compositions
|
US6022876A
(en)
*
|
1996-11-15 |
2000-02-08 |
Yale University |
L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
|
US5792773A
(en)
*
|
1996-11-15 |
1998-08-11 |
Yale University |
L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection
|
US20040044016A1
(en)
*
|
1997-01-31 |
2004-03-04 |
Mitsubishi Chemical Corporation |
Antiviral agents
|
CN1196701C
(zh)
*
|
1997-03-19 |
2005-04-13 |
埃莫里大学 |
1,3-氧硒戊环核苷的合成及抗人类免疫缺陷病毒和抗乙肝病毒活性
|
TW536403B
(en)
*
|
1997-03-24 |
2003-06-11 |
Glaxo Group Ltd |
An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
|
IT1290447B1
(it)
|
1997-03-28 |
1998-12-03 |
Zambon Spa |
Derivati 1,3-ossatiolanici ad attivita' antivirale
|
JP2001518899A
(ja)
|
1997-04-07 |
2001-10-16 |
トライアングル ファーマシューティカルズ,インコーポレイティド |
他の抗ウイルス剤との組合せにおけるmkc−442の使用
|
EP1754710A3
(fr)
|
1998-02-25 |
2007-12-19 |
Emory University |
2'-Fluoronucleosides
|
KR100954390B1
(ko)
|
1998-02-25 |
2010-04-26 |
에모리 유니버시티 |
2'-플루오로뉴클레오사이드
|
KR100856416B1
(ko)
|
1998-08-12 |
2008-09-04 |
길리애드 사이언시즈, 인코포레이티드 |
1,3-옥사티올란 뉴클레오시드의 제조 방법
|
US6979561B1
(en)
*
|
1998-10-09 |
2005-12-27 |
Gilead Sciences, Inc. |
Non-homogeneous systems for the resolution of enantiomeric mixtures
|
CN1666742A
(zh)
|
1998-11-02 |
2005-09-14 |
三角药物公司 |
对乙型肝炎病毒的联合治疗
|
KR100618028B1
(ko)
|
1998-11-05 |
2006-08-30 |
쌍트르 나쉬오날 드 라 르쉐르스 쉬앙티피끄 |
항-b형 간염 활성을 가진 뉴클레오시드
|
OA11741A
(en)
|
1998-12-23 |
2005-05-13 |
Iaf Biochem Int |
Antiviral nucleoside analogues.
|
JP2002540142A
(ja)
*
|
1999-03-29 |
2002-11-26 |
シャイアー・バイオケム・インコーポレイテッド |
白血病の処置方法
|
US6752929B1
(en)
*
|
1999-05-26 |
2004-06-22 |
Johnson Matthey Pharmaceutical Materials, Inc. |
Methods of separating FTC isomers and derivatives thereof
|
ATE235488T1
(de)
|
1999-05-26 |
2003-04-15 |
Johnson Matthey Pharmaceutical |
Verfahren zu trennung von ftc isomere und deren derivate
|
US6653318B1
(en)
|
1999-07-21 |
2003-11-25 |
Yale University |
5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
|
US6432966B2
(en)
*
|
1999-10-29 |
2002-08-13 |
Smithkline Beecham Corporation |
Antiviral combinations
|
EP1634888A3
(fr)
|
1999-11-12 |
2007-11-21 |
Pharmasset, Inc. |
Synthèse de 2'-désoxy-L-nucléosides
|
CN1919858A
(zh)
*
|
1999-11-12 |
2007-02-28 |
法玛赛特有限公司 |
2'-脱氧-l-核苷的合成
|
US6436948B1
(en)
|
2000-03-03 |
2002-08-20 |
University Of Georgia Research Foundation Inc. |
Method for the treatment of psoriasis and genital warts
|
GB0016845D0
(en)
*
|
2000-07-07 |
2000-08-30 |
Leuven K U Res & Dev |
Pharmaceutical composition for treatment of HIV infection
|
WO2003079972A2
(fr)
|
2002-02-22 |
2003-10-02 |
New River Parmaceuticals Inc. |
Systemes de distribution d'agents actifs et methodes de protection et d'administration d'agents actifs
|
WO2002051852A1
(fr)
*
|
2000-12-27 |
2002-07-04 |
Mitsui Chemicals, Inc. |
Procede de production d'un derive de saccharide non naturel
|
KR101015510B1
(ko)
*
|
2001-03-01 |
2011-02-16 |
길리애드 사이언시즈, 인코포레이티드 |
시스-ftc의 다형 및 기타 결정형
|
CA2351049C
(fr)
|
2001-06-18 |
2007-03-13 |
Brantford Chemicals Inc. |
Procede pour separer des nucleosides cis-1,3-oxathiolaniques recherches de leurs isomeres trans non desires
|
JP2003039582A
(ja)
*
|
2001-07-19 |
2003-02-13 |
Three M Innovative Properties Co |
湿潤防滑性シート及び湿潤防滑構造体
|
MY169670A
(en)
|
2003-09-03 |
2019-05-08 |
Tibotec Pharm Ltd |
Combinations of a pyrimidine containing nnrti with rt inhibitors
|
US6855346B2
(en)
*
|
2001-10-05 |
2005-02-15 |
Tzu-Sheng Wu |
Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same
|
RS51542B
(sr)
*
|
2001-10-26 |
2011-06-30 |
Istituto Di Ricerche Di Biologia Molecolare P.Angeletti Spa. |
N-supstituisani hidroksipirimidinon karboksamidni inhibitori hiv integraze
|
WO2003051298A2
(fr)
*
|
2001-12-14 |
2003-06-26 |
Pharmasset Ltd. |
Preparation d'intermediaires utiles dans la synthese de nucleosides antiviraux
|
ES2360096T3
(es)
|
2002-08-06 |
2011-05-31 |
Pharmasset, Inc. |
Procedimientos de preparación de nucleosidos de 1,3-dioxolano.
|
DE10238724A1
(de)
*
|
2002-08-23 |
2004-03-04 |
Bayer Ag |
Alkyl-substituierte Pyrazolpyrimidine
|
DE10238722A1
(de)
|
2002-08-23 |
2004-03-11 |
Bayer Ag |
Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
|
DE10238723A1
(de)
*
|
2002-08-23 |
2004-03-11 |
Bayer Ag |
Phenyl-substituierte Pyrazolyprimidine
|
US20050287177A1
(en)
*
|
2002-11-08 |
2005-12-29 |
Glaxo Group Unlimited And Smithkline Beecham Corp. |
Pharmaceutical compositions
|
BR0317113A
(pt)
*
|
2002-12-09 |
2005-10-25 |
Univ Georgia Res Found |
Timina dioxolano e combinações para uso contra cepas resistentes a 3tc/azt de hiv
|
AU2004206821C1
(en)
|
2003-01-14 |
2009-10-01 |
Gilead Sciences, Inc. |
Compositions and methods for combination antiviral therapy
|
DE10320785A1
(de)
*
|
2003-05-09 |
2004-11-25 |
Bayer Healthcare Ag |
6-Arylmethyl-substituierte Pyrazolopyrimidine
|
US8044060B2
(en)
|
2003-05-09 |
2011-10-25 |
Boehringer Ingelheim International Gmbh |
6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
|
DE102004001873A1
(de)
*
|
2004-01-14 |
2005-09-29 |
Bayer Healthcare Ag |
Cyanopyrimidinone
|
EP2258376B1
(fr)
|
2004-07-27 |
2019-02-27 |
Gilead Sciences, Inc. |
Analogues phosphonates de composés inhibiteurs du VIH
|
JP2006214695A
(ja)
*
|
2005-02-07 |
2006-08-17 |
Sanken Setsubi Kogyo Co Ltd |
空調システム
|
TWI375560B
(en)
*
|
2005-06-13 |
2012-11-01 |
Gilead Sciences Inc |
Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
|
TWI471145B
(zh)
*
|
2005-06-13 |
2015-02-01 |
Bristol Myers Squibb & Gilead Sciences Llc |
單一式藥學劑量型
|
WO2007013047A2
(fr)
*
|
2005-07-29 |
2007-02-01 |
Ranbaxy Laboratories Limited |
Compositions pharmaceutiques anti-retrovirales dispersibles dans l'eau
|
CN1328240C
(zh)
*
|
2005-08-31 |
2007-07-25 |
四川大学 |
苯甲酰氧基乙醛的制备方法
|
BRPI0617074A2
(pt)
*
|
2005-08-31 |
2011-07-12 |
Cipla Ltd |
composição farmacêutica, uso de lamivudina, nevirapina e stavudina, uso de stavudina, lamivudina e nevirapina, método para tratar uma infecção viral em um humano, método para preparar uma composição farmacêutica, método para preparar uma forma de dosagem unitária farmacêutica bicamadas e método para preparar uma forma de dosagem unitária farmacêutica tri-camadas
|
EP3159351A3
(fr)
|
2005-09-26 |
2017-05-17 |
Gilead Pharmasset LLC |
3'-azido-4'-ethynyl-nucleosides modifiés en tant qu'agents antiviraux
|
US20080317852A1
(en)
*
|
2005-12-14 |
2008-12-25 |
Amar Lulla |
Pharmaceutical Combination
|
US8895531B2
(en)
*
|
2006-03-23 |
2014-11-25 |
Rfs Pharma Llc |
2′-fluoronucleoside phosphonates as antiviral agents
|
ES2357159T3
(es)
*
|
2006-04-18 |
2011-04-19 |
Lupin Ltd. |
Forma cristalina novedosa de lamivudina.
|
EP2086955A2
(fr)
*
|
2006-10-30 |
2009-08-12 |
Lupin Ltd. |
Procédé amélioré de fabrication de lamivudine
|
KR100840495B1
(ko)
|
2007-04-13 |
2008-06-23 |
한미약품 주식회사 |
라미부딘을 입체선택적으로 제조하는 방법
|
PL2159224T3
(pl)
|
2007-06-18 |
2012-12-31 |
Ruyuan Wei Xiang Tech Co Ltd |
Tiazolilohydropirymidyny podstawione bromofenylem
|
WO2009037538A2
(fr)
*
|
2007-09-17 |
2009-03-26 |
Aurobindo Pharma Ltd |
Procédé de préparation de lamivudine de forme i
|
BRPI0820224A2
(pt)
*
|
2007-11-29 |
2015-06-16 |
Ranbaxy Lab Ltd |
Composto de fórmula iii ou seus estereoisômeros; processo para sua preparação e seu uso; uso de um composto de formula iii(a) ou iii(b) em um processo para a preparação de lamivudina de fórmula i(a) ou um composto de fórmula i(c); processo para preparação de lamivudina de fórmula i(a)
|
SI2225232T1
(sl)
*
|
2007-11-29 |
2012-12-31 |
Ranbaxy Laboratories Limited |
Postopek za pripravo substituiranih 1,3-oksatiolanov
|
JP5498392B2
(ja)
*
|
2007-11-30 |
2014-05-21 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
1,5−ジヒドロ−ピラゾロ[3,4−d]ピリミジン−4−オン誘導体及びcns障害の治療のためのpde9aモジュレーターとしてのそれらの使用
|
UA105362C2
(en)
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
TW201010692A
(en)
|
2008-06-19 |
2010-03-16 |
Public Univ Corp Nagoya City Univ |
Pharmaceutical composition for treatment or prevention of hbv infection
|
WO2010026214A1
(fr)
|
2008-09-08 |
2010-03-11 |
Boehringer Ingelheim International Gmbh |
Pyrazolopyrimidines et leur utilisation pour le traitement de troubles du snc
|
KR101687841B1
(ko)
|
2008-12-09 |
2016-12-19 |
길리애드 사이언시즈, 인코포레이티드 |
톨-유사 수용체의 조절제
|
US20110282046A1
(en)
*
|
2009-01-19 |
2011-11-17 |
Rama Shankar |
Process for preparation of cis-nucleoside derivative
|
PL2414363T3
(pl)
|
2009-03-31 |
2014-06-30 |
Boehringer Ingelheim Int |
Pochodne 1-heterocyklilo-1,5-dihydro-pirazolo[3,4-d]pirymidyn-4-onu i ich zastosowanie jako modulatorów PDE9A
|
KR101474570B1
(ko)
|
2009-04-13 |
2014-12-19 |
주식회사 대희화학 |
라미부딘의 신규한 중간체 및 이의 제조방법
|
TW201118099A
(en)
*
|
2009-08-12 |
2011-06-01 |
Boehringer Ingelheim Int |
New compounds for the treatment of CNS disorders
|
ES2540074T3
(es)
|
2009-10-14 |
2015-07-08 |
Mylan Laboratories Limited |
Proceso para la preparación de lamivudina y nuevas sales en la fabricación de la misma
|
TR201807704T4
(tr)
|
2010-01-27 |
2018-06-21 |
Viiv Healthcare Co |
Anti-viral tedavi.
|
WO2011095987A1
(fr)
|
2010-02-03 |
2011-08-11 |
Matrix Laboratories Ltd. |
Noveau procede de preparation de derive de cis-nucleoside
|
US20110223131A1
(en)
|
2010-02-24 |
2011-09-15 |
Gilead Sciences, Inc. |
Antiviral compounds
|
CN102234269B
(zh)
*
|
2010-04-29 |
2015-09-16 |
重庆医药工业研究院有限责任公司 |
拉米夫定的工业化制备方法
|
WO2011141805A2
(fr)
|
2010-05-14 |
2011-11-17 |
Lupin Limited |
Procédé de production amélioré de lamivudine
|
EP2579892A2
(fr)
|
2010-06-09 |
2013-04-17 |
Vaccine Technologies, Incorporated |
Immunisation thérapeutique chez des patients infectés par le vih recevant un traitement antirétroviral stable
|
UA110347C2
(uk)
|
2010-08-12 |
2015-12-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
ПОХІДНІ 6-ЦИКЛОАЛКІЛ-1,5-ДИГІДРОПІРАЗОЛО[3,4-d]ПІРИМІДИН-4-ОНУ І ЇХ ЗАСТОСУВАННЯ ЯК ІНГІБІТОРІВ PDE9A
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
WO2013021290A1
(fr)
|
2011-08-05 |
2013-02-14 |
Lupin Limited |
Procédé stéréosélectif de préparation de nucléosides 1,3-oxathiolane
|
WO2013168066A1
(fr)
|
2012-05-05 |
2013-11-14 |
Lupin Limited |
Procédé amélioré de fabrication de lamivudine de forme i
|
CN103694231A
(zh)
*
|
2013-11-28 |
2014-04-02 |
安徽一帆香料有限公司 |
一种拉米夫定中间体hdms的合成制备方法
|
WO2016001907A1
(fr)
|
2014-07-02 |
2016-01-07 |
Prendergast Patrick T |
Mogroside iv et mogroside v utilisables en tant qu'agonistes/stimulateurs/agents de déblocage des récepteurs toll 4 et adjuvant destiné à être utilisé dans un vaccin humain/animal et pour stimuler l'immunité contre des agents pathologiques
|
CA2954056C
(fr)
|
2014-07-11 |
2020-04-28 |
Gilead Sciences, Inc. |
Modulateurs de recepteurs de type toll pour le traitement du vih
|
WO2016033164A1
(fr)
|
2014-08-26 |
2016-03-03 |
Enanta Pharmaceuticals, Inc. |
Dérivés de nucléosides et de nucléotides
|
JP2018527366A
(ja)
|
2015-09-15 |
2018-09-20 |
ギリアード サイエンシーズ, インコーポレイテッド |
HIVを処置するためのtoll様レセプターのモジュレーター
|
ES2895951T3
(es)
|
2015-12-02 |
2022-02-23 |
Merck Sharp & Dohme |
Composiciones farmacéuticas que contienen doravirina, fumarato de tenofovir disoproxil y lamivudina
|
US11498933B2
(en)
|
2017-03-31 |
2022-11-15 |
The John Hopkins University |
Prodrug compositions
|